Like the many other scientists who have contributed to this discussion, Dr. Henrik Thomsen is entitled to express any and all honestly-held beliefs so long as his views as expressed are not knowingly indifferent to the true state of affairs.

GE Healthcare encourages such scientific debate but the imperative of a robust debate about the safety of gadolinium-based contrast agents does not license Dr. Thomsen to make knowingly false and inaccurate statements about GE Healthcare or its products. GE Healthcare initiated the lawsuit because, despite repeated efforts by GE Healthcare to engage in a constructive dialogue with Dr. Thomsen, he persisted in making false accusations that the company had deliberately concealed and suppressed information from regulatory authorities in relation to its contrast agent, Omniscan. This action is not about the science, it is about the inaccurate statements that Dr Thomsen has made about the company.

GE Healthcare has cooperated fully and actively promoted a robust evaluation of the safety of GBCAs in Europe, the United States and elsewhere based on the evidence and the science. We welcome the continuation of a principled dialogue about the safety of GBCAs.